Future Pharma: Data Science as a Strategic Partner

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a “medicines and data science company” At the beginning of 2018, Novartis CEO Vas Narasimhan spoke of reimagining Novartis as a medicines and data science com Powered by WPeMatico Continue reading Future Pharma: Data Science as a Strategic Partner

EMA Relocation Countdown: Some Industry Viewpoints

July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry. Three industr Powered by WPeMatico Continue reading EMA Relocation Countdown: Some Industry Viewpoints

Regulatory Information Management: Current and Future States

At this month’s AMPLEXOR Life Sciences Be The Expert conference in Dubrovnik, Croatia, Steve Gens of life sciences consultancy Gens & Associates talked about the evolution of Regulatory Information Management (RIM) and offered some predictions for 2022. Pharm Exec caught up Powered by WPeMatico Continue reading Regulatory Information Management: Current and Future States

Growth in the Time of Brexit: James Burt, Accord Healthcare

Accord Healthcare, which acquired Actavis UK and Ireland in 2017, is one of the fastest-growing generic pharmaceutical companies in the UK. It aims to become a Top 5 pan-EMENA (Europe, Middle East and North Africa) generics company by 2021 and has developed a specialty products commercialization Powered by WPeMatico Continue reading Growth in the Time of Brexit: James Burt, Accord Healthcare